EyePoint (EYPT) Q3 2026 earnings summary

Executive summary

• Phase 3 wet AMD trials LUGANO and LUCIA missed their primary non-inferiority endpoints versus aflibercept; the trials will close early and development focus shifts to DME.

• DME Phase 3 trials COMO and CAPRI are fully enrolled with more than 550 patients; topline results are expected in early Q4 2027.

• September 30 cash, equivalents and marketable securities totaled $118.2M; projected runway extends into late Q3 2027, while substantial doubt about going concern remains.

Financial highlights

• Q3 2026 revenue was $0.756M versus $1.0M in Q3 2025; operating expenses rose to $97.6M from $63.0M, and net loss widened to $95.6M from $59.7M.

• Q3 diluted loss per share was $1.07 versus $0.85 a year earlier; weighted-average shares increased 27% to 89.2M.

• Nine-month revenue fell to $2.0M from $30.8M; operating expenses rose to $283.4M from $203.8M, and net loss increased to $274.9M from $164.4M.

• Nine-month operating cash outflow was $229.7M versus $175.1M in 2025; ending cash, equivalents and restricted cash were $83.4M.

Outlook and guidance

• COMO and CAPRI compare DURAVYU with on-label aflibercept and use six-month redosing; the primary endpoint is BCVA change from baseline at weeks 52–56, with no futility analysis planned.

• R&D and G&A expenses are expected to decrease in 2027 following strategic prioritization and workforce reductions; separation charges are estimated at $9.0M, mostly recognized in Q4 2026.

• September 30 liquidity, post-quarter ATM proceeds and operational adjustments are expected to fund operations into late Q3 2027; additional financing is required beyond the projected runway.

• Further cost reductions, financing and business-development opportunities are under review to extend runway and preserve operations through the DME readout.